Contraceptive Technology Update – April 1, 2008
April 1, 2008
View Issues
-
FDA updates study data information on Ortho Evra contraceptive patch labeling
The Food and Drug Administration (FDA) has revised labeling on the contraceptive patch (Ortho Evra, Ortho-McNeil-Janssen Pharmaceuticals; Raritan, NJ) to include new epidemiology data on the risks of venous thromboembolism (VTE). -
Questions raised about mifepristone manufacturer
Patients seeking medication abortion using mifepristone (Mifeprex, Danco Group) may be asking questions after news agencies reported leukemia drug safety issues at a Chinese drug manufacturing firm that serves as the sole U.S. supplier of mifepristone. -
More data emerge on circumcision's impact
Data released at a recent international conference suggest that adult male circumcision, which has been seen as possibly reducing the risk of HIV transmission in Africa, could raise the risk for women there whose male partners seek the procedure after they are infected. -
New analysis confirms OC's protective effects
Good news for your patients who use oral contraceptives (OCs): A new analysis of 45 epidemiological studies shows that use of such pills during a woman's lifetime gives substantial long-term protection against ovarian cancer. -
Radar is up for new multidrug-resistant MRSA
A multidrug-resistant variant of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) bacteria is emerging in cities on both coasts of the United States, according to data from a new California-led study. -
Washington Watch: Medicaid expansions drive funding growth
Federal and state funding for family planning client services reached $1.85 billion in FY 2006, a 63% increase over 12 years, adjusting for inflation. -
Women in the dark on cervical cancer facts
Results of a new survey released by the National Association of Nurse Practitioners in Women's Health (NPWH) indicate that most of the 1,000 women polled often confused myth with fact when quizzed about cervical cancer prevention.